Call 1-844-EMPLICITI (1-844-367-5424) Call 1-844-EMPLICITI (1-844-367-5424)
BMS Access Support®

This site is intended for U.S. residents 18 years of age or older.

Call 1-844-EMPLICITI (1-844-367-5424)
BMS Access Support®

This site is intended for U.S. residents 18 years of age or older.

 

WHAT IS EMPLICITI® (elotuzumab)?

EMPLICITI is a prescription medicine used to treat multiple myeloma in combination with the medicines:

  • Revlimid® (lenalidomide) and dexamethasone in adults who have received one to three prior treatments for their multiple myeloma.
  • Pomalyst® (pomalidomide) and dexamethasone in adults who have received at least two prior treatments including Revlimid and a proteasome inhibitor.

It is not known if EMPLICITI is safe and effective in children.

POSSIBLE EMPLICITI
SIDE EFFECTs

Rick N. is an EMPLICITI patient. Denise N.,
wife. Rick takes EMPLICITI +
Revlimid® (lenalidomide) + dexamethasone.

 

KNOW THE SIDE EFFECTS THAT MAY OCCUR

Side effects may differ depending on the medication combination you are prescribed. Choose a medication combination below to view specific side effect information for each treatment.

EMPLICITI in combination with Pomalyst and dexamethasone compared with Pomalyst and dexamethasone alone.

REVIEW SIDE EFFECTS

EMPLICITI in combination with Revlimid and dexamethasone compared with Revlimid and dexamethasone alone.

REVIEW SIDE EFFECTS

What are the most common side effects?

EMPLICITI in combination with Pomalyst and dexamethasone (EPd) compared with Pomalyst and dexamethasone (Pd) alone.


These side effect rates were determined after the typical patient had received about 9 cycles of EPd or 5 cycles of Pd alone.

*At least 10% of patients receiving EPd experienced the side effects listed in the table above. Patients experienced those side effects at a 5% or greater rate than patients who took Pd alone.

YOU MAY HAVE TREATMENT-RELATED CHANGES TO YOUR BLOOD LEVELS

What are the possible changes?

EMPLICITI in combination with Pomalyst and dexamethasone (EPd) compared with Pomalyst and dexamethasone (Pd) alone.


These changes were determined after the typical patient had received about 9 cycles of EPd or 5 cycles of Pd alone.

At least 10% of patients receiving EPd experienced the side effects listed on the table above. Patients experienced those side effects at a 5% greater rate than patients who took Pd alone.

These are not all the possible side effects of EMPLICITI. If you have questions, ask your healthcare provider and read more Important Facts about EMPLICITI below and the Patient Information in the Full Prescribing Information.

What are the most common side effects?

EMPLICITI in combination with Revlimid and dexamethasone (ERd) compared with Revlimid and dexamethasone (Rd) alone.


These side effect rates were determined after the typical patient had received about 19 cycles of ERd or 14 cycles of Rd alone.

*At least 20% of patients receiving EMPLICITI with Revlimid and dexamethasone experienced the side effects listed in the table above. Patients experienced those side effects at a 5% or greater rate than patients who took Rd alone.

The percentage of patients who stopped treatment due to side effects was similar for both treatment groups (6.0% for patients who received ERd and 6.3% for patients who received Rd alone).

YOU MAY HAVE TREATMENT-RELATED CHANGES TO YOUR BLOOD LEVELS

What are the possible changes?

EMPLICITI in combination with Revlimid and dexamethasone (ERd) compared with Revlimid and dexamethasone (Rd) alone.


These changes were determined after the typical patient had received about 19 cycles of ERd or 14 cycles of Rd alone.

At least 10% of patients receiving ERd experienced the side effects listed in the table above. Patients experienced those side effects at a 5% greater rate than patients who took Rd alone.

These are not all the possible side effects of EMPLICITI. If you have questions, ask your healthcare provider and read more Important Facts about EMPLICITI below and the Patient Information in the Full Prescribing Information.

Selected Important Facts About EMPLICITI

What are the possible side effects of EMPLICITI?

EMPLICITI may cause side effects, some of which can be serious. Your healthcare team will work with you to manage any side effects you may experience throughout your treatment with EMPLICITI.

Serious side effects

Infusion reactions can happen during your EMPLICITI infusion or within 24 hours after your infusion. Symptoms of an infusion reaction may include:

  • fever
  • chills
  • rash
  • chest pain
  • trouble breathing

  • dizziness
  • light-headedness

Before every EMPLICITI infusion, your healthcare team will give you medications to help lower your chances of having an infusion reaction. If you have an infusion reaction while receiving EMPLICITI, your healthcare provider will slow or stop your infusion and treat your reaction. If you have a severe infusion reaction, your healthcare provider may decide to stop all your EMPLICITI infusions.

Call a healthcare provider or get medical help right away if you have any of the above symptoms after your infusion with EMPLICITI.

Infections may occur in patients who receive EMPLICITI + Revlimid + dexamethasone or EMPLICITI + Pomalyst + dexamethasone and can be serious. Symptoms of an infection may include:

  • fever
  • flu-like symptoms
  • cough
  • shortness of breath
  • burning with urination
  • painful skin rash

Call a healthcare provider right away if you have any signs or symptoms of an infection.

Developing new cancers (malignancies) is a risk in patients who receive EMPLICITI with Revlimid + dexamethasone or EMPLICITI with Pomalyst + dexamethasone. Your healthcare provider will check you for new cancers during your treatment with EMPLICITI.

Talk to your healthcare team to learn more about your risk of developing new cancers if you receive EMPLICITI.

Liver problems may occur. Symptoms of liver problems include:

  • tiredness
  • weakness
  • loss of appetite
  • yellowing of your skin or eyes
  • color changes in your stools
  •  
  • confusion
  • swelling of the stomach area

Your healthcare provider will do blood tests to check your liver during your treatment with EMPLICITI.

Talk to your healthcare team if you have any signs or symptoms of liver problems.

These are not all of the possible side effects of EMPLICITI. If you have questions, ask your healthcare provider and
read other Important Facts and the Full Prescribing Information.

NO MATTER WHAT YOU CAN'T QUIT.
YOU HAVE TO KEEP UP THE FIGHT.

VIEW RICK'S STORY

VIEW MORE
PATIENT STORIES

NO MATTER WHAT YOU CAN'T QUIT.
YOU HAVE TO KEEP UP THE FIGHT.

VIEW RICK'S STORY

VIEW MORE PATIENT STORIES

Rick N., EMPLICITI patient, and his family. Rick takes EMPLICITI + Revlimid® (lenalidomide) + dexamethasone.

What financial resources are available?

Resources to help pay for EMPLICITI may be available to you.

FINANCIAL RESOURCES

Important Facts About EMPLICITI® (elotuzumab)

EMPLICITI in combination with
Revlimid® (lenalidomide) and dexamethasone or in combination with Pomalyst® (pomalidomide) and dexamethasone may cause the following serious side effects:
Infusion reactions, infections, risk of developing new cancers (malignancies), and liver problems. There are also other serious risks associated with Revlimid and Pomalyst to females and males of reproductive potential, including possible serious birth defects or death of an unborn baby, and specific requirements regarding birth control, pregnancy testing and blood and/or sperm donation. For more information, please read the Important Facts throughout this website or by expanding this section. Your healthcare team will work with you to manage any side effects you may experience throughout your treatment with EMPLICITI.

This is a summary of important information that you need to know about EMPLICITI. Your healthcare team can work with you to help answer any questions you may have about EMPLICITI.

Keep this information in a safe place, so you can refer to it before and during your treatment. Look out for these icons as you read:

Talk to your healthcare teamCall a healthcare provider right awayHelpful information to remember
What is EMPLICITI?

EMPLICITI is a prescription medicine used with other medications to treat the following types of adult patients with multiple myeloma:

People who have received 1-3 prior treatments for their multiple myeloma may receive:

EMPLICITI
(elotuzumab)
  Revlimid®
(lenalidomide)
  dexamethasone

People who have received at least 2 prior treatments, including Revlimid and a proteasome inhibitor, may receive:

EMPLICITI
(elotuzumab)
  Pomalyst®
(pomalidomide)
  dexamethasone

Remember to read the safety information for the other medications you are receiving.

The safety and effectiveness of EMPLICITI have not been studied in children.

What are the possible side effects of EMPLICITI?

EMPLICITI may cause side effects, some of which can be serious. Your healthcare team will work with you to manage any side effects you may experience throughout your treatment with EMPLICITI.

Serious side effects

Infusion reactions can happen during your EMPLICITI infusion or within 24 hours after your infusion. Symptoms of an infusion reaction may include:

  • fever
  • chills
  • rash
  • chest pain
  • trouble breathing

  • dizziness
  • light-headedness

Before every EMPLICITI infusion, your healthcare team will give you medications to help lower your chances of having an infusion reaction. If you have an infusion reaction while receiving EMPLICITI, your healthcare provider will slow or stop your infusion and treat your reaction. If you have a severe infusion reaction, your healthcare provider may decide to stop all your EMPLICITI infusions.

Call your healthcare provider or get medical help right away if you have any of the above symptoms after your infusion with EMPLICITI.

Infections may occur in patients who receive EMPLICITI + Revlimid + dexamethasone or EMPLICITI + Pomalyst + dexamethasone and can be serious. Symptoms of an infection may include:

  • fever
  • flu-like symptoms
  • cough
  • shortness of breath
  • burning with urination
  • painful skin rash

Call a healthcare provider right away if you have any signs or symptoms of an infection.

Developing new cancers (malignancies) is a risk in patients who receive EMPLICITI with Revlimid + dexamethasone or EMPLICITI with Pomalyst + dexamethasone. Your healthcare provider will check you for new cancers during your treatment with EMPLICITI.

Talk to your healthcare team to learn more about your risk of developing new cancers if you receive EMPLICITI.

Liver problems may occur. Symptoms of liver problems include:

  • tiredness
  • weakness
  • loss of appetite
  • yellowing of your skin or eyes
  • color changes in your stools
  •  
  • confusion
  • swelling of the stomach area

Your healthcare provider will do blood tests to check your liver during your treatment with EMPLICITI.

Talk to your healthcare team if you have any signs or symptoms of liver problems.

The most common side effects

The most common side effects of EMPLICITI when used with Revlimid + dexamethasone include:

  • fatigue
  • diarrhea
  • fever
  • constipation
  • cough
  • numbness, weakness, tingling, or burning pain in your arms or legs
  • sore throat or runny nose
  • upper respiratory tract infection
  • decreased appetite
  • pneumonia

The most common side effects of EMPLICITI when used with Pomalyst + dexamethasone include:

  • constipation
  • high blood sugar

These are not all of the possible side effects of EMPLICITI.

Call your doctor for medical advice about side effects.

You can report any side effects you experience to the FDA by calling
1-800-FDA-1088.

What should I discuss with my healthcare team before starting EMPLICITI?

Talk to your healthcare team about all of your medical conditions, including if you have an infection.

Let your healthcare team know as soon as possible if you are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. It is not known if EMPLICITI can harm an unborn baby. However, Revlimid and Pomalyst may cause birth defects or death of an unborn baby. It is not known if EMPLICITI passes into breastmilk. You should not breastfeed during treatment with EMPLICITI + Revlimid + dexamethasone or with EMPLICITI + Pomalyst + dexamethasone.

Before receiving EMPLICITI + Revlimid + dexamethasone, or EMPLICITI + Pomalyst + dexamethasone, females and males must agree to the instructions in the Revlimid REMS® program or the Pomalyst REMS® program, depending on which combination was prescribed for you. The programs have specific requirements about birth control (contraception), pregnancy testing, blood donation, and sperm donation that you need to know.

Talk to your healthcare team to learn more about Revlimid or Pomalyst.

Interactions with other drugs may affect the way EMPLICITI works in your body.

Talk to your healthcare team about all the medicines you take, including:

  • prescription medicines
  • over-the-counter medicines
  • vitamins
  • herbal supplements

Please read the Patient Information in the Full Prescribing Information.

689US1803829-03-01 04/19

  • Dexamethasone:

    A steroid used in the treatment of multiple myeloma, often in combination with other medications. To learn more about dexamethasone, ask your healthcare team.

  • Immunotherapy:

    A type of treatment that works with your immune system to help control certain cancers. It is different because it is not surgery, radiation, or traditional chemotherapy.

  • Intravenous (IV) infusion:

    When medicine is given directly into the bloodstream through a vein—usually in the arm, hand, or through an IV port.

  • M protein:

    A type of protein made by myeloma cells. M protein levels may be used to estimate the extent of myeloma disease, and measuring them is one way to evaluate response to myeloma treatments.

  • Natural Killer (NK) Cell:

    A type of white blood cell that helps fight infection or disease and can be important for destroying cancerous cells.

  • Overall response rate:

    The percentage of patients who responded to treatment—for example, patients whose level of M protein was lowered by a certain amount. Overall response rates include stringent complete response, complete response, very good partial response, and partial response.

  • Progression-free survival:

    The length of time during and after treatment of a disease that a patient lives with the disease but it does not get worse.

  • REVLIMID

     (ALSO KNOWN AS LENALIDOMIDE):

    An oral medication with anti-myeloma effects. It is used in combination with other medications. To learn more about Revlimid, ask your healthcare team.

  • Pomalyst (also known as pomalidomide):

    An oral medication with anti-myeloma effects. It is used in combination with other medications. To learn more about Pomalyst, ask your healthcare team.